IN THE NEWS

Dr. Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and Director of Oncology at CureLab Oncology Inc., recently presented new clinical findings at the 27th Congress of the European Society of Gynaecological Oncology (ESGO 2026) in Copenhagen, highlighting a promising therapeutic advance for women with platinum-resistant ovarian cancer (PROC).

Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease

At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer (PROC); one of the most aggressive and treatment-refractory settings in gynecologic oncology.

Alexander Shneider, founder and CEO of CureLab Oncology, Inc. shared a post on LinkedIn: “We are honored to see our recent clinical data featured in EMJ Oncology. For patients with platinum‑resistant ovarian cancer – one of the most challenging diagnoses in oncology – these findings point toward what may become a meaningful paradigm shift.

Adding therapy to chemo shown to extend survival in small cancer trial

In this episode of the Talking Biotech podcast, host Dr. Kevin Folta engages with Dr. Alex Schneider, CEO and founder of CureLab, to discuss innovative approaches to cancer treatment, particularly focusing on the challenges posed by refractory cancers such as triple-negative breast cancer and platinum-resistant ovarian cancer.

Elenagen, developed by biotech firm CureLab Oncology, is designed to modulate the immune response and target cancer-associated inflammation.

Elenagen, a novel DNA immunotherapy doubles survival time for ovarian cancer patients in breakthrough Phase II study. Elenagen, a first-in-class plasmid DNA therapy (immunotherapy), in combination with standard gemcitabine chemotherapy increased median overall survival (OS) from 13 months to over 25 months in patients with tough ovarian cancers.() The data come from findings published in the International Journal of Gynecological Cancer.

All received standard gemcitabine chemotherapy, and half also received elenagen, being developed by CureLab Oncology, as a once-weekly injection into the muscle.

All received standard gemcitabine chemotherapy, and half also received elenagen, being developed by CureLab Oncology, as a once-weekly injection into the muscle.

Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say. The 30 women in the study had ovarian cancer resistant to first-line platinum-based chemo drugs, along with elevated blood levels of a cancer protein called CA-125.

Health Rounds: Experimental drug doubles survival of ovarian cancer patients in trial Feb 13 (Reuters) – Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say.

Feb 13 (Reuters) – Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say. The 30 women in the study had ovarian cancer resistant to first-line platinum-based chemo drugs, along with elevated blood levels of a cancer protein called CA-125.

Feb 13 (Reuters) – Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say. The 30 women in the study had ovarian cancer resistant to first-line platinum-based chemo drugs, along with elevated blood levels of a cancer protein called CA-125.

All received standard gemcitabine chemotherapy, and half also received elenagen, being developed by CureLab Oncology, as a once-weekly injection into the muscle.

In this interview from the sidelines of the Biotech Showcase in San Francisco last month, Alexander Schneider, CEO of CureLab Oncology, shares both.

Toutes ont reçu une chimiothérapie standard à base de gemcitabine, et la moitié d’entre elles ont également reçu de l’élénagène, développé par CureLab Oncology, sous forme d’une injection hebdomadaire dans le muscle.

Gabriel Levin, gynaecologic oncologist at the McGill University Health Centre, and Director of Oncology at CureLab Oncology Inc. will present new clinical findings at the 27th Congress of the European Society of Gynaecological Oncology (ESGO 2026) in Copenhagen, highlighting a promising therapeutic advance

Alexander Shneider, CEO of CureLab Oncology and the inventor of Elenagen, emphasizes the evolutionary significance of this therapy.

Clinical Relevance: Adding elenagen to gemcitabine significantly prolonged survival without added toxicity in platinum-resistant ovarian cancer, supporting further investigation of elenagen-based immunomodulation in combination with chemotherapy.

In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection. … How Elenagen works against cancer Elenagen’s ability to reduce chronic inflammation alters the intratumoral microenvironment, facilitating the penetration of immune cells (Tumor-Infiltrating Lymphocytes, or TILs).

Posted in Podcasts | Tagged CureLab Oncology, DNA, endogene.bio, Endometriosis, Genetics, Junevity, MHRA, Ocular diseases, Oncology, Regulatory, UK government, University of California San Francisco, Women’s health The latest episode of the DDW Highlights Podcast is now available to listen to below

Elenagen is a plasmid therapy—a small, circular piece of DNA encoding the protein p62/SQSTM1 — currently being developed by the firm CureLab Oncology, Inc. In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection.

Elenagen emerged from ‘serendipitous discoveries’ Elenagen, developed by biotech company CureLab Oncology, works by reducing chronic inflammation and altering the intratumoral environment, facilitating the penetration of immune cells (tumour-infiltrating lymphocytes, or TILs).

Elenagen is a plasmid therapy—a small, circular piece of DNA encoding the protein p62/SQSTM1 — currently being developed by CureLab Oncology, Inc. In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection.

In planned U.S. and EU trials, CureLab will offer Elenagen for 24 months, as data suggests further treatment may offer no additional benefit.

Os pesquisadores avaliaram uma nova terapia baseada em DNA, Elenagen, administrada em combinação com a quimioterapia padrão gencitabina em mulheres com PROC e CA-125 elevado.

Elenagen is a plasmid therapy—a small, circular piece of DNA encoding the protein p62/SQSTM1—currently being developed by CureLab Oncology, Inc. In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection.

Elenagen, a DNA-based therapy, works by targeting specific genetic pathways involved in cancer progression.

Researchers say their ability to create Elenagen was only possible because of their opposition to dominant biotech doctrine

As the terrible Ukraine-Russia situation evolves, what does this portend for scientists located in the region? Scientists from countries with differing political systems have long collaborated with colleagues located in politically distressed and war-torn regions. Despite the associated challenges, these collaborations have combined their respective strengths and even leveraged the unique characteristics of their regional differences.